Serum adiponectin levels and ambulatory blood pressure monitoring in pediatric renal transplant recipients

Transplantation

Volumn 88, Issue 8, 2009, Pages 1030-1037

  Sethna, Christine B ^a   Leonard, Mary B ^a,b   Gallagher, Paul R ^a   Meyers, Kevin E C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adiponectin; Blood pressure; Hypertension.; Pediatric; Renal transplantation

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MALE; OBESITY; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; UNIVARIATE ANALYSIS;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE MONITORING, AMBULATORY; BODY WEIGHT; CHILD; CROSS-SECTIONAL STUDIES; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TRANSPLANTATION; MONITORING, PHYSIOLOGIC; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 70350441410     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b9e1ec     Document Type: Article

References (66)

1. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponectin-A key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264.
2. Wang Y, Lam KS, Yau MH, et al. Post-translational modifications of adiponectin: Mechanisms and functional implications.Biochem J 2008; 409: 623.
3. Nishimura R, Morimoto A, Matsudaira T, et al. Ratio of high-, medium-, and low-molecular weight serum adiponectin to the total adiponectin value in children. J Pediatr 2007; 151: 545.
4. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79.
5. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51: 8.
6. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arte-rioscler Thromb Vasc Biol 2000; 20: 1595.
7. Lim HS, Tayebjee MH, Tan KT, et al. Serum adiponectin in coronary heart disease: Ethnic differences and relation to coronary artery disease severity. Heart 2005; 91: 1605.
8. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764.
9. Chen MP, Tsai JC, Chung FM, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 821.
10. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens 2005; 18 (12 Pt 1): 1543.
11. Beauloye V, Zech F, Tran HT, et al. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab 2007; 92: 3025.
12. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectine-mia with impaired vasoreactivity. Hypertension 2003; 42: 231.
13. Ohashi K, Kihara S, Ouchi N, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108.
14. Mallamaci F, Zoccali C, Cuzzola F, et al. Adiponectin in essential hypertension. J Nephrol 2002; 15: 507.
15. Adamczak M, Wiecek A, Funahashi T, et al. Decreased plasma adi-ponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72.
16. Bakkaloglu SA, Soylemezoglu O,Buyan N,etal. Adiponectin levels and arteriosclerotic risk factors in pediatric renal transplant recipients. Pe-diatr Transplant 2006; 10: 187.
17. Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: A 5-year prospective study. Hypertension 2007; 49: 1455.
18. Della Mea P, Lupia M, Bandolin V, et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005; 18: 30.
19. Huang KC, Chen CL, Chuang LM, et al. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab 2003; 88: 4130.
20. Imatoh T, Miyazaki M, Momose Y, et al. Adiponectin levels associated with the development of hypertension: A prospective study. Hypertens Res 2008; 31: 229.
21. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318.
22. Kazumi T, Kawaguchi A, Sakai K, et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25: 971.
23. Li HY, Chiu YF, Hwu CM, et al. The negative correlation between plasma adiponectin and blood pressure depends on obesity: A family-based association study in SAPPHIRe. Am J Hypertens 2008; 21: 471.
24. Shaibi GQ, Cruz ML, Weigensberg MJ, et al. Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J Clin Endocrinol Metab 2007; 92: 1809.
25. Shankar A, Marshall S, Li J. The association between plasma adiponec-tin level and hypertension. Acta Cardiol 2008; 63: 160.
26. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independentofbody mass index, in the Japanese population. Clin Sci (Lond) 2002; 103: 137.
27. Sung SH, Chuang SY, Sheu WH, et al. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity. Hypertens Res 2008; 31: 633.
28. Dogru T, Sonmez A, Tasci I, et al. Plasma adiponectin and insulin resistance in new onset hypertension. Endocrine 2006; 29: 405.
29. Gillum RF. The association of the ratio of waist to hip girth with blood pressure, serum cholesterol and serum uric acid in children and youths aged 6-17 years. J Chronic Dis 1987; 40: 413.
30. Goldbacher EM, Matthews KA, Salomon K. Central adiposity is associated with cardiovascular reactivity to stress in adolescents. Health Psychol 2005; 24: 375.
31. Mitsnefes MM. Hypertension and end-organ damage inpediatric renal transplantation. Pediatr Transplant 2004; 8: 394.
32. Hanevold CD,HoPL, TalleyL,Mitsnefes MM. Obesity and renal transplant outcome: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 2005; 115: 352.
33. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76.
34. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147.
35. Hoffstedt J, Arvidsson E, Sjolin E, et al. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 2004; 89: 1391.
36. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104: 849.
37. Fernandez JR, Redden DT, Pietrobelli A, et al. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004; 145: 439.
38. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for disease control and prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002; 109: 45.
39. Krebs NF, Jacobson MS. Prevention of pediatric overweight and obesity. Pediatrics 2003; 112: 424.
40. Morris N, Udry J. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 1980; 9: 271.
41. Tanner JM. Assessment of skeletal maturity and prediction of adult height (TW2 method). London, Academic Press 1975.
42. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990; 44: 45.
43. Thayu M, Shults J, Burnham JM, et al. Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2007; 13: 1121.
44. Jensen MD, Kanaley JA, Reed JE, et al. Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorp-tiometry. Am J Clin Nutr 1995; 61: 274.
45. Furler SM, Poynten AM, Kriketos AD, et al. Independent influences of central fat and skeletal muscle lipids on insulin sensitivity. Obes Res 2001; 9: 535.
46. Urbina E, Alpert B, Flynn J, et al. Ambulatory blood pressure monitor-ingin children and adolescents: Recommendations for standard assessment: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity inYouth Committeeof the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 2008; 52: 433.
47. Soergel M, Kirschstein M, Busch C, et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: A multicenter trial including 1141 subjects. J Pediatr 1997; 130: 178.
48. Sorof JM, Cardwell G, Franco K, et al. Ambulatory blood pressure and left ventricular mass index inhypertensive children.Hypertension2002; 39: 903.
49. Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. BMJ 1995; 310: 170.
50. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2 Suppl 4th Report): 555.
51. Belsha CW, Wells TG, McNiece KL, et al. Influence of diurnal blood pressure variations on target organ abnormalities in adolescents with mild essential hypertension. Am J Hypertens 1998; 11 (4 Pt 1): 410.
52. McNiece KL, Gupta-Malhotra M, Samuels J, et al. Left ventricular hypertrophy in hypertensive adolescents: Analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension 2007; 50: 392.
53. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765.
54. Tanida M, Shen J, Horii Y, et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood) 2007; 232: 390.
55. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: The role of systolic and pulse pressures. J Hypertens 2003; 21: 1841.
56. Patel JV, Lim HS, Hughes EA, et al. Adiponectin and hypertension: A putative link between adipocyte function and atherosclerotic risk? J Hum Hypertens 2007; 21: 1.
57. Martos-Moreno GA, Barrios V, Argente J. Normative data for adi-ponectin, resistin, interleukin 6, and leptin/receptor ratio in a healthy Spanish pediatric population: Relationship with sex steroids. Eur J En-docrinol 2006; 155: 429.
58. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734.
59. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamy-cin inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl Int 2007; 20: 305.
60. Fantuzzi G. Adiponectin and inflammation: Consensus and controversy. J Allergy Clin Immunol 2008; 121: 326.
61. Puzik A, Schultz C, Iblher P, et al. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr 2007; 96: 1483.
62. Sun Q, Liu Q, Zheng Y, et al. Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 2008; 45: 2929.
63. Adamczak M, Szotowska M, Chudek J, et al. Plasma adiponectin concentration in patients after successful kidney transplantation-A single-center, observational study. Clin Nephrol 2007; 67: 381.
64. Teplan V, Schuck O, Stollova M, et al. Obesity and adiponectin after kidney transplantation. Acta Physiol Hung 2007; 94: 149.
65. Chudek J, Adamczak M, Karkoszka H, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186.
66. Shen YY, Charlesworth JA, Kelly JJ, et al. The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007; 56: 1201